DelveInsight launched a new report on Adrenoleukodystrophy Market Insights, Epidemiology and Market Forecast 2030.
DelveInsight’s ‘Adrenoleukodystrophy Market Report 2030’ delivers an in-depth understanding of the Adrenoleukodystrophy, historical and forecasted epidemiology as well as the Adrenoleukodystrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Adrenoleukodystrophy is an X-linked recessive genetic disorder caused by the abnormality in the ABCD1 gene present on the X chromosome that leads to the accumulation of very long-chain fatty acids (VLCFAs) in the brain, nervous system, and adrenal gland. The accumulation of VLCFAs leads to the deterioration of the myelin sheath, and without the sheath, neurons cannot conduct action potentials, this leads to the development of seizures and hyperactivity. Currently, no drug is approved for the treatment of Adrenoleukodystrophy and the available treatment options include hormone replacement therapy, dietary therapy with Lorenzo’s oil and Hematopoietic stem cell transplantation, using either umbilical cord or bone marrow stem cells.
View our full report: https://www.delveinsight.com/report-store/adrenoleukodystrophy-market
Adrenoleukodystrophy Symptoms:
- Attention deficit hyperactivity disorder
- Epilepsy
- Autism
- Other learning disabilities
Request for a detailed sample copy of the report: https://www.delveinsight.com/sample-request/adrenoleukodystrophy-market
“Among the European five countries, Germany had the highest diagnosed prevalent population of ALD with 1,895 cases, followed by France and the United Kingdom. On the other hand, Italy had the lowest diagnosed prevalent population of 1,126 in 2017.”
Adrenoleukodystrophy Emerging Therapy Assessment:
1. Lenti D: Bluebird Bio
2. Leriglitazone: Minoryx Therapeutics, S.L.
The market size for ALD was USD 993 million in 2017 in the Seven Major Markets.
DelveInsight’s analysts estimate that the market is expected to experience a significant rise in the coming years.
Although, a noticeable growth can be seen in the upcoming year, owing to the launch of Lenti-D (Gene therapy; Bluebird Bio), and Leriglitazone (MIN-102) (Minoryx Therapeutics).
“The total market size of Adrenoleukodystrophy in Japan was USD 111.57 million in 2017.”
Table of contents
1 Key Insight
2 Executive Summary of Adrenoleukodystrophy
3 Adrenoleukodystrophy Market Overview at a Glance
4 Disease Background and Overview: Adrenoleukodystrophy
5 Case Reports
6 Adrenoleukodystrophy Epidemiology and Patient Population
7 United States Epidemiology
8 EU5 Epidemiology
9 Japan Epidemiology
10 Current Adrenoleukodystrophy Treatment and Medical Practices
11 Unmet needs
12 Adrenoleukodystrophy Marketed Drugs
13 Adrenoleukodystrophy Emerging Drugs
14 Adrenoleukodystrophy 7MM Market Analysis
15 United States
16 EU-5 countries: Market Outlook
17 Japan Market Outlook
18 Adrenoleukodystrophy Market Drivers
19 Adrenoleukodystrophy Market Barriers
20 SWOT Analysis
21 Reimbursement and market access
22 Appendix
23 DelveInsight Capabilities
24 Disclaimer
25 About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performanc
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/